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1This edition of Advance 
highlights the fact 
that the University of 
Tennessee Medical 
Center and UT Graduate 
School of Medicine are 
involved in collaborative 
research with other 
institutions.  Our 
research enterprise has 
grown so vast that partnering with different 
organizations often is the most robust way to 
focus diverse expertise on a single problem. 
 Our institutions collaborate with the 
University of Tennessee, Knoxville, College 
of Engineering, School of Public Health, 
Department of Nutrition and College of 
Veterinary Medicine, as well as Oak Ridge 
National Laboratory (ORNL) and the UT 
Health Science Center in Memphis to name 
a few.  The valuable partnerships formed by 
these joint efforts lead to better research.  These 
partnerships also yield an advantage in obtaining 
funding from national organizations.  
 Many human medical problems can be solved 
through engineering solutions or have analogies 
in the veterinary world, where solutions benefit 
both human and non-human patients.  The 
juxtaposition of clinicians and basic scientists 
in diverse fields often creates a relationship that 
advances research in problems found in clinical 
care.  Having the computational and nuclear 
expertise of ORNL close by enables sophisticated 
approaches to complex medical issues.  
 The Graduate School of Medicine is uniquely 
poised to take advantage of these resources, and 
as part of an academic medical center, we are 
using collaborative opportunities to advance our 
knowledge, understanding and treatment of the 
ailments of our patients.
Mitchell Goldman, M.D.
Assistant Dean for Research
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Wisdom for Your Life.
fEATuREd RESEARCHER »»»»»»
Amy LeBlanc and husband, Casey, enjoy reading with 
their daughters, Erica and Isabelle.  LeBlanc’s research that 
combines animal and human health is unique in the world.
We need to know what normal looks like 
before we can understand abnormal.
~Amy LeBlanc
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 Some people have it.  Some simply do not.  It’s 
a deep sense of curiosity.  It’s asking, “Why” and 
“What if” and not being satisfied until an answer 
is found.  
 Thankfully, Amy LeBlanc, D.V.M., associate 
professor and director of Translational Research, 
Molecular Imaging and Translational Research 
Program, possesses that deep curiosity and the 
education and skills to act upon it to the benefit of 
patients.  But the unique part of LeBlanc’s story is 
that for her, patients are both the two-legged and 
four-legged varieties.
 In a unique joint position with the UT 
Graduate School of Medicine and the UT College 
of Veterinary Medicine, LeBlanc studies non-
invasive ways to detect and monitor response to 
treatment for diseases in dogs, and in front of 
her is an ever-widening field of opportunities to 
translate her findings to the detection and care of 
diseases in humans.
Academic to Begin With
 LeBlanc’s father is a chemical engineer, and her 
mother is a teacher. 
 “I think my parents would say I was academic 
to begin with, and I loved animals and science 
from a young age,” says LeBlanc with a quick 
laugh that fills the room.  
 For most of her life, LeBlanc thought she 
would become a veterinarian in a private practice.  
Eventually, her sense of curiosity told her otherwise.
 During her veterinary school years, LeBlanc 
became fascinated with oncology and decided 
she wanted to delve into that specialty by 
pursuing additional post-graduate training.  After 
completing a medical oncology residency, LeBlanc 
began practicing veterinary oncology in Tampa, 
Florida.  While she enjoyed the work, she had “a 
nagging feeling that this can’t be all there is,” she 
says.  “I realized I wanted to be on the edge of 
what’s known and what’s not known.”
A Curious Turn of Events
 In May 2004, she and husband, Casey, a 
veterinary clinical pathologist, moved to Knoxville 
to accept faculty positions at the UT College of 
Veterinary Medicine.
 “Almost never are two positions like those 
The Curiosity of   Amy LeBlanc? ?
One of Amy LeBlanc’s current research programs is 
inflammatory brain disease in dogs and how to draw 
correlation to human health.
We need to know what normal looks like 
before we can understand abnormal.
~Amy LeBlanc
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open at the same time,” LeBlanc says in 
amazement.  “It just never happens.  But 
we are lucky to be here in Knoxville.” 
 In line with a typical tenure-track 
faculty position at the Veterinary Medical 
Center, LeBlanc was able to begin research 
while fulfilling clinical service and 
teaching roles.  She soon learned about 
incredible technology available just across 
the Tennessee River at the UT Graduate 
School of Medicine, and by 2009, with 
the encouragement of James Neutens, 
Ph.D., dean of the Graduate School of 
Medicine, and James Thompson, D.V.M., 
Ph.D., dean of the College of Veterinary 
Medicine, LeBlanc had a joint appointment 
between the two institutions, doing what she 
loves:  Answering “what if.”
 “It was a natural progression to where I wanted to 
focus my research efforts,” LeBlanc says.  “We have a 
unique set of resources, technology and people that 
you cannot find anywhere else in the world.”
Understanding Abnormal
 LeBlanc is putting this unique environment 
to good use.  Her goal is to help researchers in 
various fields realize the potential of PET/CT 
(Positron Emission Tomography/Computed 
Tomography) imaging.  She sees a big picture not 
many medical or veterinary professionals see or 
know exists:  Knowledge gained from using PET/
CT imaging for human health can help animals; 
conversely, using PET/CT and new PET tracers 
to diagnose and monitor treatment in animals can 
further human health.
 “Animals with spontaneous diseases, like 
heart failure, diabetes and cancer, can help us 
understand similar diseases in humans.  We have 
incredible technology and expertise here, so 
we should be asking, ‘How else can we use this 
technology to benefit both?’.”
 LeBlanc has high demands for her research:  
In addition to complying with all regulations 
governing research, it must be both 
ethically sound and mutually beneficial for 
veterinary medicine and human medicine.  
Protocols are followed and regularly scrutinized.
 At present, LeBlanc is using the non-invasive 
PET/CT imaging facility to determine how 
normal dog brains use glucose for fuel, so she and 
others around the world can compare with brain 
activity of dogs suspected of having inflammatory 
brain disease. 
 “We need to know what normal looks like 
before we can understand abnormal,” she says.
 This study is one of several headed by LeBlanc 
that is unique in the world.  Nowhere else and 
no one else in the world has ever done such 
studies.  She recounts a time recently when she 
attended an international conference and watched 
as her research findings were used to support the 
presenter’s findings.
 “It was an exciting moment, knowing 
the work we are doing here is impacting the 
way physicians think about diagnosing and 
treating their patients,” says LeBlanc.  “In the 
end, I’d like to see drugs and imaging tools 
come into the marketplace for humans and 
animals, understanding the knowledge we gain 
is transferrable to both.  Someone’s mother or 
brother will get that drug, which would not 
be available if we hadn’t been here, if we hadn’t 
wondered about the possibilities.”
The Curiosity of   Amy LeBlanc
Why this matters:
In Tennessee, gestational diabetes affects up to 14% 
of pregnancies, and more than one of every three 
women in East Tennessee is obese.  Research that 
brings healthier babies into the world, who go home 
with healthier mothers, affects generations.
 Healthier Moms     and Babies:
Research is Moving Dreams to Reality
You might call the folks in the 
Department of Obstetrics/
Gynecology determined 
dreamers.  
 They are Bobby Howard, 
M.D., chair of the department;  
Jo Kendrick, W.H.N.P.-B.C., 
certified diabetes educator; and 
Dawn Coe, Ph.D., University 
of Tennessee, Knoxville, 
Department of Kinesiology, 
Recreation and Sport Studies.  
Through two research 
programs, this group is tackling 
gestational diabetes and obesity, 
two health issues that threaten 
the lives and health of pregnant 
women and their babies.
 If only everyone dreamed as 
these professionals do.
  In 2009, Kendrick and 
Coe teamed to determine the 
effect of moderate activity on 
controlling gestational diabetes.  
Maintaining blood glucose 
in pregnant women means 
healthier moms and babies.
 “My dream is to determine how many steps 
it takes each day to maintain normal blood 
glucose levels in women with gestational diabetes 
to avoid the use of insulin during pregnancy,” 
Kendrick says.
 First, Kendrick and Coe validated a pedometer 
that could be used to accurately count the daily 
steps of pregnant women.  Then, eight pregnant 
women who had gestational diabetes enrolled in 
the research study, and throughout the first 
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Dawn Coe, Ph.D., Bobby Howard, M.D., and Jo Kendrick, 
W.H.N.P.-B.C., are tackling gestational diabetes and obesity 
to help ensure healthy moms and babies.
 Healthier Moms     and Babies:
part of 2011, each woman had her blood glucose 
continuously monitored during moderate-
intensity walking and sedentary trials.  
 “The results were significant,” Coe says.  
“We learned that moderate activity only 
one time each day sustained lower blood 
glucose levels for up to three hours.”
 Now, the next phase—a larger 
cohort who will undergo different levels 
of prescribed activity and monitoring—
will continue through 2013.
 Obesity is another health threat 
to women and babies’ health during 
pregnancy, one that Bobby Howard, 
M.D., dreams of eradicating.  
 “We know that during 
pregnancy, obesity results in 
complications including a higher rate of 
Cesarean delivery, surgical complications, 
anesthesia complications and impaired 
wound healing,” Howard says.  “The baby’s 
health also is compromised with an increased risk 
of birth defects, macrosomia and stillbirth.”
 Howard has embarked on a research program 
that will help educate pregnant women about the 
risks of obesity to their and their babies’ health as 
well as help them monitor their diet and activity 
levels.  Using today’s technology helps.
 Each woman in the study has been provided 
pedometers and an internet-capable device for 
documenting their daily activity and food intake 
on a specially designed web site.  Howard and 
others will access the information to help their 
patients understand how to adjust their lifestyles 
to combat obesity—and have healthier babies.
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Using p5 peptide developed by Jonathan Wall, Ph.D., amyloid in a mouse model glows brightly in a PET scan.  The peptide can 
breach the blood-brain barrier and is helping researchers determine the cause of Alzheimer’s and other diseases.
Peptide p5 is the only 
imaging agent in the 
world to bind the sugar 
molecules in amyloid or 
tumors.  It is unique.
See Plaque in the Brain
An urgent Need:
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 Jonathan Wall, Ph.D., a professor and director 
of Preclinical and Diagnostic Molecular Imaging 
Laboratory and his collaborators, Steven Kennel, 
Ph.D., and Amy 
LeBlanc, D.V.M., 
have developed 
and are testing new 
imaging agents that 
might be good for 
patients who suffer from amyloid-related diseases 
like Alzheimer’s disease and Type 2 diabetes, as 
well as certain cancers, such as melanoma. 
 People with Alzheimer’s and Type 2 diabetes 
develop amyloid, a substance comprised of sticky 
protein fibers and sugar molecules.  Doctors 
are uncertain what role amyloid plays in these 
diseases, but they believe it causes destruction 
of brain cells and the insulin-making cells in the 
pancreas.  Because of 
this uncertainty, there 
is an urgent need to 
see the sticky substance 
to accurately diagnose 
and stage disease and 
monitor therapies patients are using.  Until now, 
seeing amyloid in these patients occurred only in 
autopsies.  
 Wall has developed a new peptide imaging 
agent, a tiny protein he’s named “p5.”  This 
peptide seeks out and binds special sugar 
Why this matters:
While p5 does not yet destroy amyloid, it does bind 
to every type of amyloid.  It brings us one giant 
leap closer to understanding Alzheimer’s disease 
and diabetes and in developing rapid methods 
for accurate diagnosis and treatment strategies, 
leading ultimately to a cure for amyloid-associated 
diseases and cancer.
Jonathan Wall, Ph.D.
7
molecules that are found in amyloid deposits and 
surprisingly on certain tumor cells, including 
melanoma tumors.  Under the right conditions, 
the p5 peptide can breach the blood-brain barrier 
and through PET (positron emission tomography) 
scans and other techniques has been shown in 
preclinical tests to stick to amyloid in the brains of 
animals with Alzheimer’s-like disease.
 Wall expects that with appropriate 
modifications, p5 may eventually image amyloid 
in patients with Alzheimer’s disease and diabetes 
better than other imaging agents because it can 
specifically seek the amyloid.  Peptide p5 is 
the only imaging agent in the world to bind 
the sugar molecules in amyloid or tumors.  
It is unique.
 In addition, Wall and Kennel have 
been able to detect melanoma tumors on 
animals that are brought by their owners for 
care. LeBlanc uses this technique to assist in 
the diagnosis and monitoring of dogs suffering 
with melanoma.
 “In the U.S., our ability to detect amyloid 
deposits is limited,” said Wall. “We’ve made 
amazing progress, but we need to move faster.  P5 
is the next generation of amyloid imaging agents, 
and it holds much promise for helping people 
with Alzheimer’s and diabetes as well as those 
suffering from certain forms of cancer.”
Why this matters:
Clinical trials provide answers to patients and 
physicians and help develop new treatments for a 
variety of medical conditions.
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Clinical trials are 
medical research 
that helps bring new 
devices, vaccines or 
drugs more quickly to 
patients.  As part of an 
academic medical center 
environment, physicians 
and researchers at the 
Graduate School of 
Medicine conduct 
clinical trials to pursue 
answers for their patients and advance the field of 
medicine overall.
 Scott Stevens, M.D., is a professor in the 
department of Surgery and a passionate researcher 
in vascular pathology.  He heads the University of 
Tennessee Medical Center Aorta Center, the only 
site in East Tennessee to be selected to participate in 
an FDA-approved clinical trial studying stent repair 
of Acute Complicated Type B Aortic Dissections 
(Medtronic Dissection Trial—U.S. Study).  This 
is an investigational device, limited by Federal (or 
United States) law to investigational use.   
 This study represents a joint effort of the 
cardiothoracic, vascular and endovascular services 
at the Aorta Center to provide available options 
to treat patients with this highly challenging and 
lethal disease.  The trial currently is enrolling.
 Stevens also leads several registry programs, 
which are post-approval studies of devices in use.  
One registry is assessing outcomes of the use of 
stents with distal protection in the treatment of 
obstructive carotid artery disease.  Another is 
assessing the use of thrombectomy with varying 
catheter lengths for patients with peripheral 
vascular disease; embolism and thrombosis; or 
venous thrombosis.
 For more information about these studies, 
contact Susan Rawn, coordinator, Clinical 
Research, at 865-305-9227.
 Clinical trials at the University of Tennessee 
Medical Center also are ongoing.  One trial 
currently under way investigates the recurrence of 
tumors in patients with non-small cell lung cancer. 
The trial, called MAGRIT, is sponsored by 
GlaxoSmithKline, a pharmaceutical company, and 
is being conducted at several centers around the 
world.  Currently open for enrollment, MAGRIT 
evaluates an investigational lung cancer treatment 
called MAGE-A3 ASCI (antigen-specific cancer 
immunotherapeutic).  ASCI works with the 
patient’s own immune system to fight the cancer.  
In this study, the treatment specifically targets 
the MAGE-A3 antigen, which is a substance 
sometimes found on lung cancer cells.
 The purpose of MAGRIT is to measure how 
well the MAGE-A3 ASCI works in preventing 
cancer from coming back when given to patients 
with non-small cell lung cancer whose tumors 
express MAGE-A3 and who have had tumors 
removed by surgery.
 For more information about the MAGRIT 
clinical trial, contact Barbara Munsey, director, 
Research Compliance and Oncology Clinical 
Trials, at 865-305-7136.  
A comprehensive list of clinical trials being  
conducted across the country can be found at  
www.clinicaltrials.gov. 
Clinical Trials: 
 Providing Answers 
Why this matters:
Research into the root cause of Huntington’s 
disease and Type 2 diabetes can be the first step 
in eliminating these diseases that affect millions 
of Americans and for people with Huntington’s 
disease is always fatal.  This research also can 
lead to discoveries in other amyloid-associated 
diseases, such as Alzheimer’s and Parkinson’s.
Valerie Berthelier, Ph.D.
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In a major 
breakthrough, 
Valerie 
Berthelier, 
Ph.D., assistant 
professor and 
director of the 
Graduate School 
of Medcine’s 
Conformational 
Diseases and 
Therapeutics 
Laboratory, in 
collaboration 
with Christopher Stanley, Ph.D., Neutron 
Scattering Science Division at Oak Ridge 
National Laboratory (ORNL), are the first in 
the world to image the earliest formation of 
the mutant huntingtin protein.  This protein 
is believed to be responsible for causing 
Huntington’s disease, a hereditary neurological 
disorder that is always fatal and affects one in 
10,000 Americans, and this earliest formation of 
the protein is believed to be the most toxic.  
 Using a neutron-scattering instrument at 
ORNL, the team was able to learn how the 
protein begins aggregating.  Researchers believe 
that once the mutant protein forms aggregates, 
or clumps, the brain cannot naturally remove 
them, leading to Huntington’s disease.
 Now that the toxic proteins have been 
revealed, the next step is to develop drugs to 
combat the formation of clumps or remove the 
toxicity of the initial protein.  This knowledge 
also will aid in the study of other protein-
aggregation diseases, including Alzheimer’s and 
Parkinson’s.
 Berthelier also is investigating the aggregation 
of amyloid (dangerous fibrils) in the pancreas, 
ultimately to draw a link to Type 2 diabetes.
 The pancreas is a gland shaped much like 
a bunch of grapes that is located behind the 
stomach.  It aids in protein digestion and 
produces insulin directly into the bloodstream to 
help the body metabolize carbohydrates.  
 When the pancreas cannot produce insulin 
or the body does not properly use the insulin 
produced, Type 2 diabetes results.  But what is 
the cause of the pancreas malfunctioning?
 Berthelier and her team know patients with 
Type 2 diabetes have deposits of amyloid in their 
pancreases. While the association of pancreatic 
amyloid and development of Type 2 diabetes is 
known, a direct causative role for the amyloid has 
not been established.
 Does the amyloid polypeptide in the pancreas 
cause Type 2 diabetes?
 The researchers are investigating the 
aggregation properties of the amyloid and 
identifying small compounds that can alter the 
aggregation phenomena. 
Breakthroughs in Huntington’s 
Disease, Type 2 Diabetes
Christopher Stephens, Ph.D., 
leads a growing field of medical 
research: regenerative medicine.
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 Christopher P. Stephens, Ph.D., is leading  
a new research program that is growing… 
quite literally.  
 Regenerative medicine is a field of science 
that began in earnest in the 1990s.  It combines 
medicine and engineering to help the body heal 
itself using the body’s own cells to regenerate 
organs or tissue.   It can be used for skin injuries, 
neuromuscular disorders, joint replacements, 
cartilage regrowth and organ repair.
 In his work, Stephens, a research assistant 
professor in the Department of Surgery and 
the Center for Materials Processing at the UT 
College of Engineering, along with collaborator 
Madhu Dhar, Ph.D., at the UT College of 
Veterinary Medicine, are developing methods 
to induce regeneration using equine stem cells.  
Stem cells are not fully differentiated, so they 
have the ability to grow into different tissue 
types, including bone, muscles and connective 
tissue.  Stephens’s work requires the use of adult 
donated stem cells, not embryonic stem cells, 
and horses are used because their physiology is 
similar to human conditions and can provide 
therapeutic benefit to the companion animal.  
 In the novel research, stem cells are painlessly 
removed from a horse and placed in culture 
with a scaffold created by Stephens.  With the 
ultimate goal of creating scaffolds that encourage 
cell growth for various uses, currently Stephens is 
conducting initial compatibility testing. 
 “Our initial scaffold allowed for cell growth 
primarily on the 
surface,” Stephens 
said.  “That was 
promising, but 
the cell growth 
needs to infiltrate 
the scaffold in 
order to produce 
a tissue.  We are 
now developing 
a scaffold that 
is a naturally 
degradable polymer with a pore structure to 
enable in-growth of cells.  Once we’ve achieved 
adequate cell adhesion and growth, that material 
will be placed in a horse to promote healing of 
the animal’s bone fracture or wound.”
 Success means the horse’s body begins 
healing itself by regenerating cells using those 
implanted—not healing with scar tissue but with 
new, healthy tissue.
 For Stephens, this is just the beginning.  
Relying on funding and FDA approval, he 
eventually will use regenerative medicine 
to create vascular bypass vessels and tissue-
engineered venous valves.   To that end, he is 
developing a bioreactor with collaborators at 
the University of Houston, which will provide 
chemical and biomechanical signals to the cells, 
mimicking a natural environment.  Testing of 
cell regeneration in this bioreactor should begin 
in May 2012.
The Growth of Regenerative Medicine
IN BRIEf »»»»»»
Why this matters:
Last year in America, more than 112,000 
people waited for organ transplants.  Work in 
regenerative medicine will allow for treatment 
of diseases that are currently untreated due to 
organ/tissue shortages.  It also will promote new 
treatments for diseases, such as diabetes and 
heart disease.  By learning how tissue grows, 
disease processes can be better understood, 
leading to more targeted treatments for patients.  
Comparing x-ray images and forensic anthropological skeletal specimens helps link dental pathology to systemic diseases.  Shown 
here are x-ray and skeletal evidence of a failed root canal resulting in infection in the body.
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 Dentists have long been able to see how diseases 
of the teeth and gums affect the body, but now, 
our research is revealing that systemic disease can 
first be spotted in the mouth. 
 The department of General Dentistry’s Gary 
McCown, D.D.S., assistant professor, O. Lee 
Wilson, D.M.D., associate professor, and Murray 
Marks, Ph.D., associate professor, are applying 
dental science to forensic anthropological skeletal 
specimens from the Regional Forensic Center 
and University of Tennessee’s Body Farm.  The 
team is comparing long-term dental and alveolar 
(tooth socket) bone diseases with radiographic 
appearance and medical records. This study may 
lead to further evidence linking dental pathology 
to other systemic diseases like diabetes, heart 
disease, stroke and cancer. 
Using Forensic Science to 
Solve Dentistry Mysteries
Why this matters:
Dentists at the UT Graduate School of Medicine 
are learning that the first signs of systemic 
disease may be witnessed in the gums, teeth and 
underlying bone tissue. With this knowledge, 
dental patients can be referred to medical 
specialists who may diagnose systemic disease 
sooner or prevent it altogether.
IN BRIEf »»»»»»
Students and researchers work collaboratively in the Collmann Medical Student Education Endowment.  The 2011 participants 
include (Front) Michael Karlstad, Ph.D.; Roger Carroll, Ph.D.; Wissam Tobea; Vincent Irish; (Back) Caroline Conley; Jerrin 
Nabers; Valerie Berthelier, Ph.D.; and Deidra Mountain, Ph.D.  Not pictured is Robert Craft, M.D.
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IN BRIEf »»»»»»
 Empowering medical students with a passion 
for research and an understanding of how 
research affects patient care was the hope of  
I. Reid Collmann, M.D., former dean of the UT 
Graduate School of Medicine.  To help bring that 
hope to reality, the Collmann Medical Student 
Education Endowment gives young future 
doctors time in research labs, working alongside 
experienced researchers.
 First- and second-year medical students and 
pre-medicine students in undergraduate school 
can apply for the eight-week summer program at 
the Graduate School of Medicine.  Last summer, 
four students participated, studying in a variety 
of specialities.
 Students chosen for the 2011 program and 
their respective research topics include 
 Caroline Conley:  Human Nutrition
 Vincent Irish:  Medicine and Vascular Disease
 Jerrin Olivia Nabers:  Nutrition and Anesthesiology
 Wissam Tobea:  Conformational Diseases 
 Graduate School of Medicine faculty who 
mentored the students include
 Valerie Berthelier, Ph.D.
 Roger Carroll, Ph.D.
 Robert Craft, M.D.
 Michael Karlstad, Ph.D.
 Deidra Mountain, Ph.D.
 For information on the Collmann 
Endowment, contact Missy Maples, Student 
Affairs coordinator, at 865-305-9618.
Medical Students Learn 
Passion for Research
Why this matters:
Creating passion for research and patient care is 
an integral part of educating well prepared and 
compassionate physicians.
Your Chance to Advance
 The people at the UT Graduate School of Medicine would be happy to discuss 
our research programs and how your support can help advance healthcare.  For 
information about philanthropic giving to the UT Graduate School of Medicine 
Office of Research, please contact the development office at 865-305-6611 or 
development@utmck.edu. 
 If you would like more information about any of the research programs described in 
this issue of Advance, please contact the UT Graduate School of Medicine at 865-305-
9290 or visit us online: http://gsm.utmck.edu/research/main.cfm.                                               
        Thank you.
David Stern, M.D.,  
Executive Dean
Christy Lawson, M.D.
ExEcutivE DEan commEnts  
on FuturE oF rEsEarch
 Professionals at the UT 
Graduate School of Medicine 
received clear direction from 
David M. Stern, M.D., 
executive dean and interim 
vice chancellor for research 
at the UT Health Science 
Center during a recent visit to 
Knoxville:  Partnerships.
 “The only way to succeed in this economic 
and healthcare atmosphere is to partner with the 
[University of Tennessee Medical Center] and the 
community,” Stern said.  “Research endeavors need 
to add value to [patient care] now more than ever.”
 Stern called for a redefined research mission, one 
that supports comparative effectiveness research for 
patient-centered outcomes. 
 The UT Graduate School Medicine will 
continue to refine the direction of its programs.  
By dovetailing many of the institution’s research 
programs with the Centers of Excellence at the 
University of Tennessee Medical Center, research 
will continue to grow, and the clinical programs at 
the centers will be able to provide more cutting-
edge patient care.
rEsEarch in nicu tEchnology, 
cornEal DEFEct rEcEivE FunDing
 Research being conducted by Christopher P. 
Stephens, Ph.D., research assistant professor, and 
others has received recognition and funding from 
the Morris Animal Foundation.  The research 
investigates new methods using adult donated stem 
cells and scaffolding to repair corneal ulceration in 
horses, the most common eye problem in humans, 
horses, dogs and cats.
 Stephens, Vichien Lorch, M.D., and Mark 
Gaylord, M.D., also received funding from 
the University of Tennessee for technology 
development to aid premature infants in neonatal 
intensive care.  The work is in collaboration with 
the Department of Mechanical Engineering at the 
University of Houston.  
 This research includes the development of four 
new technologies:
 Soft Hydrated Coating for Cannula:  The 
coating is developed from cellulose in Stephens’s 
laboratory and should improve the seal in infants’ 
nostrils.
 Computer-diagnostic Stethoscope:  The novel 
computer-interfaced stethoscope will detect heart 
and lung sounds of premature infants.  Using 
digital recorders on the stethoscopes, the team will 
be able to use the heart and lung sounds to create 
diagnostic software. 
 Apnea Stimulation Device: A new device will 
interface with infants’ apnea monitors to gently 
stimulate infants when Apnea of Prematurity  
is detected.
 Breathing-assist Chest Plate:  Using a soft 
polymer to form a seal against the infant’s skin and 
create a slight vacuum, the chest plate will facilitate 
respiration.  The chest-plate technology could 
eliminate the use of endotracheal tubes. 
Burn rEsEarch FunDED
Christy Lawson, M.D., 
instructor in the Department 
of Surgery, received the 
Norman Yoshimura Grant 
from the American Society 
of Parenteral and Enteral 
Nutrition Rhoads Research 
Foundation for her work 
on the connection between 
angiotensin and insulin in 
burn trauma.  
 Often in burn trauma, insulin resistance is 
increased.  The study investigates the crosstalk 
between angiotensin—a hormone that raises blood 
pressure—and insulin to regulate glucose levels and 
aid in treatment of victims of burns.
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